170 related articles for article (PubMed ID: 30249386)
1. Dilemma of elevated CA 19-9 in biliary pathology.
Tsen A; Barbara M; Rosenkranz L
Pancreatology; 2018 Dec; 18(8):862-867. PubMed ID: 30249386
[TBL] [Abstract][Full Text] [Related]
2. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
3. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
4. Caution in interpretation of the tumor marker CA 19.9 in patients with obstructive jaundice: illustrative case reports.
Helling TS
J Miss State Med Assoc; 2013 Apr; 54(4):96-9. PubMed ID: 23767270
[TBL] [Abstract][Full Text] [Related]
5. Bile levels of carcino-embryonic antigen in patients with hepatopancreatobiliary disease.
Buffet C; Fourré C; Altman C; Prat F; Fritsch J; Choury A; Briantais MJ; Desgrez A; Etienne JP
Eur J Gastroenterol Hepatol; 1996 Feb; 8(2):131-4. PubMed ID: 8723416
[TBL] [Abstract][Full Text] [Related]
6. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
Kim MS; Jeon TJ; Park JY; Choi J; Shin WC; Park SE; Seo JY; Kim YM
Korean J Gastroenterol; 2017 Aug; 70(2):96-102. PubMed ID: 28830135
[TBL] [Abstract][Full Text] [Related]
7. CA 19-9 assay in patients with extrahepatic cholestatic jaundice.
Barone D; Onetto M; Conio M; Paganuzzi M; Saccomanno S; Aste H; Pugliese V
Int J Biol Markers; 1988; 3(2):95-100. PubMed ID: 3243982
[TBL] [Abstract][Full Text] [Related]
8. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
[TBL] [Abstract][Full Text] [Related]
9. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
10. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease.
Zabron AA; Horneffer-van der Sluis VM; Wadsworth CA; Laird F; Gierula M; Thillainayagam AV; Vlavianos P; Westaby D; Taylor-Robinson SD; Edwards RJ; Khan SA
Am J Gastroenterol; 2011 Sep; 106(9):1711-7. PubMed ID: 21670771
[TBL] [Abstract][Full Text] [Related]
12. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
13. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
Ng WW; Tong KJ; Tam TN; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of bile cytology in the diagnostic management of patients with biliary tract obstruction.
Cobb CJ; Floyd WN
Acta Cytol; 1985; 29(2):93-100. PubMed ID: 2984868
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of indeterminate biliary strictures.
Bowlus CL; Olson KA; Gershwin ME
Nat Rev Gastroenterol Hepatol; 2016 Jan; 13(1):28-37. PubMed ID: 26526122
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.
Goonetilleke KS; Siriwardena AK
Eur J Surg Oncol; 2007 Apr; 33(3):266-70. PubMed ID: 17097848
[TBL] [Abstract][Full Text] [Related]
17. CA 19-9 to rule out pancreatic or biliary cancer among patients with cholestasis: an unsuitable test?
Madonia S; Aragona E; Maisano S; Montalbano L; Olivo M; Rossi F; Restivo G; Cottone M
Dig Dis Sci; 2007 Apr; 52(4):1125-7. PubMed ID: 17342388
[No Abstract] [Full Text] [Related]
18. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
19. Outcome of stenting in biliary and pancreatic benign and malignant diseases: A comprehensive review.
Mangiavillano B; Pagano N; Baron TH; Luigiano C
World J Gastroenterol; 2015 Aug; 21(30):9038-54. PubMed ID: 26290631
[TBL] [Abstract][Full Text] [Related]
20. Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
Shoda J; Matsuda A; Shida T; Yamamoto M; Nagino M; Tsuyuguchi T; Yasaka T; Tazuma S; Uchiyama K; Unno M; Ohkohchi N; Nakanuma Y; Kuno A; Narimatsu H
J Gastroenterol; 2017 Feb; 52(2):218-228. PubMed ID: 27358229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
